ReviewPharmaceuticals (Basel, Switzerland)2026
Pharmacological Exploration of Traditional Chinese Medicine and Tujia Ethnomedicine in Rheumatoid Arthritis Therapy: From Historical Clinical Wisdom to Contemporary Scientific Inquiry.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Rheumatoid arthritis (RA) remains a recalcitrant clinical challenge, as modern therapies are often hampered by adverse effects, suboptimal responses, and failure to achieve radical cure. Traditional Chinese Medicine (TCM) and Tujia ethnomedicine, with centuries of accumulated experience in managing RA (classified as "Bi Syndrome" in TCM), offer distinct theoretical frameworks and abundant therapeutic resources. TCM emphasizes syndrome differentiation-based holistic regulation, while Tujia ethnomedicine relies on indigenous medicinal plants and empirically derived therapies shaped by its unique geographical context. This review aims to accelerate the integration of traditional wisdom with contemporary pharmacology for the development of novel RA therapies. A comprehensive literature search was performed across PubMed, Web of Science, CNKI, and ethnomedical monographs to synthesize data on their theoretical underpinnings, therapeutic strategies, mechanisms of action, and clinical efficacy. TCM and Tujia ethnomedicine possess significant anti-RA effects, characterized by multi-component, multi-target synergistic mechanisms that complement modern medicine. However, they face common challenges including unclear material bases of active components, insufficient standardized clinical evidence, and inadequate quality control protocols. This review provides a critical foundation for integrating TCM/Tujia ethnomedicine with modern pharmacology, highlighting the urgent need for further research to clarify active constituents, establish standardized protocols, and validate clinical efficacy-ultimately facilitating the development of safer, more effective RA therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.